triptorelin, goserelin, leuprorelin — Competitive Intelligence Brief

triptorelin, goserelin, leuprorelin (triptorelin, goserelin, leuprorelin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist. Area: Oncology.

phase 3 GnRH agonist GnRH receptor Oncology Small molecule

Target snapshot

triptorelin, goserelin, leuprorelin (triptorelin, goserelin, leuprorelin) — Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic. Triptorelin, goserelin, and leuprorelin are synthetic analogs of gonadotropin-releasing hormone (GnRH) that act as potent agonists, initially stimulating and then downregulating GnRH receptors, leading to a decrease in gonadotropin secretion and subsequently a decrease in sex hormone production.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
triptorelin, goserelin, leuprorelin TARGET	triptorelin, goserelin, leuprorelin	Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic	phase 3	GnRH agonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
Leuprolide acetate in depot suspension	Leuprolide acetate in depot suspension	Colorado Center for Reproductive Medicine	marketed	GnRH agonist	GnRH receptor
Ovulation triggering with GnRH-a+rhCG	Ovulation triggering with GnRH-a+rhCG	Fundación Santiago Dexeus Font	marketed	Gonadotropin-releasing hormone agonist combined with recombinant human chorionic gonadotropin	GnRH receptor (for GnRH-a component); LH/hCG receptor (for rhCG component)
Half-Dose Depot Triptorelin	Half-Dose Depot Triptorelin	Tehran University of Medical Sciences	marketed	GnRH agonist	GnRH receptor
Leuprolide Depot	Leuprolide Depot	Enteris BioPharma Inc.	marketed	GnRH agonist	GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2028-03-22 — Lupron · 9617303 · US
• 2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH agonist class)

1. Takeda · 4 drugs in this class
2. Abbott · 3 drugs in this class
3. Ipsen · 3 drugs in this class
4. Changchun GeneScience Pharmaceutical Co., Ltd. · 3 drugs in this class
5. University of Pisa · 2 drugs in this class
6. Chong Qing Reproducive and Genetic Institute · 1 drug in this class
7. Chesapeake Urology Research Associates · 1 drug in this class
8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
9. Enteris BioPharma Inc. · 1 drug in this class
10. Colorado Center for Reproductive Medicine · 1 drug in this class